https://www.foxbusiness.com/technology/regeneron-c
Post# of 148183
Isn't moderate to severe where leronlimab has shown it's greatest success? It's halfway through its Ph 3 trial and has been proven safe in nearly 1000 patients. If someone has COVID for a given number of days, their lungs and other major organs will be seriously impacted and they are more likely to be a "long hauler".
I do not comprehend the FDA's decision making process. Multiple BP companies have failed or had less than stellar results compared to Cytodyn. What am I missing? I'm not looking for a political response, although politics plays an obvious role. What does leronlimab need to do to escape from FDA jail and continues its mitigation successes? Does Cytodyn have to enroll and treat the full 395 patients before it is taken seriously? Is there a statistically significant number less than 395? What does the board think?